Treatment of small cell lung cancer

Jairam Krishnamurthy, Tsewang Tashi, Wilson Gonsalves, Apar Kishor P Ganti

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Small cell lung cancer (SCLC) represents approximately 16 percent of all lung cancers and occurs almost exclusively in smokers. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment. SCLC is highly responsive to multiple chemotherapeutic drugs, and chemotherapy dramatically prolongs survival compared to best supportive care. Randomized trials have shown a survival benefit for combination regimens compared to single agent chemotherapy, and for simultaneous administration of multiple agents as compared to sequential administration of the same agents. While no specific combination has established superiority in the treatment of SCLC, based upon efficacy and toxicity profiles, platinum-based combinations are generally preferred. For patients with limited stage SCLC who are candidates for aggressive therapy, thoracic radiotherapy (RT) administered concurrently with systemic chemotherapy can be used for initial management. For patients with evidence of continuing response at the completion of chemoradiotherapy, prophylactic cranial irradiation is recommended. Second-line chemotherapy may improve survival and quality of life in patients with relapsed or recurrent SCLC, even in patients who do not achieve an objective response. Several single agents and combination regimens have activity in recurrent SCLC. However, the optimal regimen is unclear, and responses generally are short. For patients with relapsed disease and a good performance status, single agent topotecan therapy is recommended. Various targeted therapies, cancer vaccines, and novel cytotoxic agents are currently being evaluated for their role in SCLC.

Original languageEnglish (US)
Title of host publicationLung Cancer Treatment
PublisherNova Science Publishers, Inc.
Pages111-124
Number of pages14
ISBN (Print)9781613241318
StatePublished - Apr 1 2011

Fingerprint

Chemotherapy
Small Cell Lung Carcinoma
Cells
Radiotherapy
Drug Therapy
Chemoradiotherapy
Topotecan
Therapeutics
Cancer Vaccines
Cytotoxins
Survival
Platinum
Toxicity
Cranial Irradiation
Irradiation
Lung Neoplasms
Thorax
Pharmaceutical Preparations
Quality of Life
Recurrence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Krishnamurthy, J., Tashi, T., Gonsalves, W., & Ganti, A. K. P. (2011). Treatment of small cell lung cancer. In Lung Cancer Treatment (pp. 111-124). Nova Science Publishers, Inc..

Treatment of small cell lung cancer. / Krishnamurthy, Jairam; Tashi, Tsewang; Gonsalves, Wilson; Ganti, Apar Kishor P.

Lung Cancer Treatment. Nova Science Publishers, Inc., 2011. p. 111-124.

Research output: Chapter in Book/Report/Conference proceedingChapter

Krishnamurthy, J, Tashi, T, Gonsalves, W & Ganti, AKP 2011, Treatment of small cell lung cancer. in Lung Cancer Treatment. Nova Science Publishers, Inc., pp. 111-124.
Krishnamurthy J, Tashi T, Gonsalves W, Ganti AKP. Treatment of small cell lung cancer. In Lung Cancer Treatment. Nova Science Publishers, Inc. 2011. p. 111-124
Krishnamurthy, Jairam ; Tashi, Tsewang ; Gonsalves, Wilson ; Ganti, Apar Kishor P. / Treatment of small cell lung cancer. Lung Cancer Treatment. Nova Science Publishers, Inc., 2011. pp. 111-124
@inbook{2a2b0a204ee3426899a1e69d53f837c2,
title = "Treatment of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) represents approximately 16 percent of all lung cancers and occurs almost exclusively in smokers. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment. SCLC is highly responsive to multiple chemotherapeutic drugs, and chemotherapy dramatically prolongs survival compared to best supportive care. Randomized trials have shown a survival benefit for combination regimens compared to single agent chemotherapy, and for simultaneous administration of multiple agents as compared to sequential administration of the same agents. While no specific combination has established superiority in the treatment of SCLC, based upon efficacy and toxicity profiles, platinum-based combinations are generally preferred. For patients with limited stage SCLC who are candidates for aggressive therapy, thoracic radiotherapy (RT) administered concurrently with systemic chemotherapy can be used for initial management. For patients with evidence of continuing response at the completion of chemoradiotherapy, prophylactic cranial irradiation is recommended. Second-line chemotherapy may improve survival and quality of life in patients with relapsed or recurrent SCLC, even in patients who do not achieve an objective response. Several single agents and combination regimens have activity in recurrent SCLC. However, the optimal regimen is unclear, and responses generally are short. For patients with relapsed disease and a good performance status, single agent topotecan therapy is recommended. Various targeted therapies, cancer vaccines, and novel cytotoxic agents are currently being evaluated for their role in SCLC.",
author = "Jairam Krishnamurthy and Tsewang Tashi and Wilson Gonsalves and Ganti, {Apar Kishor P}",
year = "2011",
month = "4",
day = "1",
language = "English (US)",
isbn = "9781613241318",
pages = "111--124",
booktitle = "Lung Cancer Treatment",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Treatment of small cell lung cancer

AU - Krishnamurthy, Jairam

AU - Tashi, Tsewang

AU - Gonsalves, Wilson

AU - Ganti, Apar Kishor P

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Small cell lung cancer (SCLC) represents approximately 16 percent of all lung cancers and occurs almost exclusively in smokers. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment. SCLC is highly responsive to multiple chemotherapeutic drugs, and chemotherapy dramatically prolongs survival compared to best supportive care. Randomized trials have shown a survival benefit for combination regimens compared to single agent chemotherapy, and for simultaneous administration of multiple agents as compared to sequential administration of the same agents. While no specific combination has established superiority in the treatment of SCLC, based upon efficacy and toxicity profiles, platinum-based combinations are generally preferred. For patients with limited stage SCLC who are candidates for aggressive therapy, thoracic radiotherapy (RT) administered concurrently with systemic chemotherapy can be used for initial management. For patients with evidence of continuing response at the completion of chemoradiotherapy, prophylactic cranial irradiation is recommended. Second-line chemotherapy may improve survival and quality of life in patients with relapsed or recurrent SCLC, even in patients who do not achieve an objective response. Several single agents and combination regimens have activity in recurrent SCLC. However, the optimal regimen is unclear, and responses generally are short. For patients with relapsed disease and a good performance status, single agent topotecan therapy is recommended. Various targeted therapies, cancer vaccines, and novel cytotoxic agents are currently being evaluated for their role in SCLC.

AB - Small cell lung cancer (SCLC) represents approximately 16 percent of all lung cancers and occurs almost exclusively in smokers. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment. SCLC is highly responsive to multiple chemotherapeutic drugs, and chemotherapy dramatically prolongs survival compared to best supportive care. Randomized trials have shown a survival benefit for combination regimens compared to single agent chemotherapy, and for simultaneous administration of multiple agents as compared to sequential administration of the same agents. While no specific combination has established superiority in the treatment of SCLC, based upon efficacy and toxicity profiles, platinum-based combinations are generally preferred. For patients with limited stage SCLC who are candidates for aggressive therapy, thoracic radiotherapy (RT) administered concurrently with systemic chemotherapy can be used for initial management. For patients with evidence of continuing response at the completion of chemoradiotherapy, prophylactic cranial irradiation is recommended. Second-line chemotherapy may improve survival and quality of life in patients with relapsed or recurrent SCLC, even in patients who do not achieve an objective response. Several single agents and combination regimens have activity in recurrent SCLC. However, the optimal regimen is unclear, and responses generally are short. For patients with relapsed disease and a good performance status, single agent topotecan therapy is recommended. Various targeted therapies, cancer vaccines, and novel cytotoxic agents are currently being evaluated for their role in SCLC.

UR - http://www.scopus.com/inward/record.url?scp=84892790717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892790717&partnerID=8YFLogxK

M3 - Chapter

SN - 9781613241318

SP - 111

EP - 124

BT - Lung Cancer Treatment

PB - Nova Science Publishers, Inc.

ER -